EC approves Roche's Gazyvaro for first-line CLL

The European Commission approved Gazyvaro obinutuzumab from Roche (SIX:ROG; OTCQX:RHHBY) in combination with chlorambucil for first-line chronic lymphocytic leukemia (CLL) in patients unsuitable for f...